High Mobility Group Protein B1 (HMGB1) (HRP)

HMGB1 is one of the signature danger signals of endogenous cellular injury, and is released outside the cell by necrotic and inflammatory cells to act as a chemoattractant for immature dendritic cells (DCs), promoting their maturation. DCs can also secrete HMGB1, promoting proliferation and Th1 polarization of interacting T cells. Cellular injury resulting in necrosis, leads to passive HMGB1 release, and microbes or pro-inflammatory cytokines may later stimulate active release from APCs.
HMGB1 is emerging as a prime specific marker and regulator of necrotic cell death, possibly through the PI3KC3-MEK-ERK pathway. It interacts directly with the autophagy protein Beclin-1, and binds to receptors, such as RAGE on endothelial cells, and Toll-like receptors on macrophages. Studies identifying microtubule-associated protein 1 light chain 3 (LC3) lipidation and redistribution, coupled with the accumulation of autophagosomes and autolysosomes, have shown an important role for HMGB1 release in sustaining autophagy. Studies have also shown that HMGB1 released after chemotherapy treatment is a critical regulator of autophagy, and a potential drug target for therapeutic interventions in leukemia.

Applications:
Suitable for use in Immunofluorescence and Western Blot. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Store product at 4°C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C. Aliquots are stable at -20°C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Note: Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Note: Applications are based on unconjugated antibody.